Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Rheumatology Physician in Mendon, MA
NPI: 1376708032Primary Practice Location
UMASS MEMORIAL MEDICAL CENTER/UNIVERSITY CAMPUS
55 Lake Ave N, Worcester, MA
Primary Employer
Umass Memorial Medical Group, Inc.
triamcor.com
HQ Phone
Get M.D. Roberto's Phone Numberphone_androidMobile
Get M.D. Roberto's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
MA State Medical License
2022 - 2027
PA State Medical License
2005 - 2022
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Rheumatology
Temple University Hospital
Residency • Internal Medicine
2008 - 2014
Fellowship • Rheumatology
2012 - 2013
University of Cattolica del Sacro Cuore
Medical School
Until 1993
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 58 | 70 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 25 | 25 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 20 | 20 |
Authors: Bloostein, Aliza, Caricchio, Roberto
Journal: ACR Open Rheumatol
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Intervention / Treatment: BIOLOGICAL: BNT162b2, Bivalent, DRUG: Withhold IS (B cell depletion therapy), BIOLOGICAL: Ad26.COV2.S, BIOLOGICAL: Moderna mRNA-1273, BIOLOGICAL: BNT162b2, DRUG: Continue IS (MMF or MPA), DRUG: Continue IS (MTX), BIOLOGICAL: Continue IS (B cell depletion therapy), BIOLOGICAL: Monovalent [B.1.351] CoV2 preS dTM-AS03, DRUG: Withhold IS (MMF or MPA), DRUG: Withhold IS (MTX), BIOLOGICAL: Moderna mRNA-1273, Bivalent
Lead Sponsor: Swedish Orphan Biovitrum
Intervention / Treatment: BIOLOGICAL: Anakinra, BIOLOGICAL: Emapalumab
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc., Corbus Pharmaceuticals Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: JBT-101
